The clinical challenges of synthetic cathinones by Amira, Guirguis
The title  
Title: The clinical challenges of synthetic 
cathinones 
 
Authors: Schifano Fabrizio1, Napoletano Flavia2, Arillotta Davide1, Zangani 




1 Psychopharmacology, Drug Misuse and Novel Psychoactive Substances 
Research Unit, School of Life and Medical Sciences, University of 
Hertfordshire, Hatfield, UK  
2 East London Foundation Trust (ELFT), Homerton University Hospital, 
London, UK 
3 Department of Health Sciences, University of Milan, Milan, Italy 
4 Gabalfa Clinic, Cardiff and Vale NHS Health Board, Cardiff, UK 
5 Swansea University Medical School; Institute of Life Sciences; Swansea, 
UK 
6 Addictions' Observatory (ODDPSS), Rome, Italy  
7 Guglielmo Marconi University, Rome, Italy 
8 Department of Mental Health, ASL Roma 2, Rome, Italy  
 
Corresponding Author contact information 
John M Corkery; 0044 (0)1707 281053 
Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances 
Research Unit, School of Life and Medical Sciences, University of 
Hertfordshire, College Lane Campus, Hatfield AL10 9AB, UK. 
j.corkery@herts.ac.uk 
 
The authors confirm that the Principal Investigator for this paper is 
Fabrizio Schifano and that he had direct responsibility for the drafting of 
this paper; no direct contact or clinical care activities were conducted 
relating to the current project 
 
Running head: Cathinones; quantification and concerns 
 
Key words: new psychoactive substances; NPS; synthetic cathinones; 
drug-induced aggression; drug misuse; drug prevention. 
 
Word count: 4376; Figures: 0; Tables: 0; Appendices: 2 
  
Abstract  
Within the new psychoactive substances (NPS) scenario, several hundreds 
of different molecules, mostly including synthetic cannabinoids and 
cathinones, have so far been identified. The aims of the paper were to: 
(a) identify the number of synthetic cathinones mentioned in a range of 
psychonaut, NPS-related, online sources; and (b) describe the associated 
acute/long term clinical scenario and the related treatment/management 
plan.  
After about 18 months of operation and exclusion of false 
positives/duplicates, some 4204 unique NPS molecules were included in 
the ‘NPS.Finder® crawling/navigating software database. Most popular 
NPS included: 1265 psychedelic phenethylamines (30.1%; CI 95%: 28.7-
31.5%); 1253 synthetic cannabinoids (29.8%; CI 95%: 28.4-31.2%); 
429 synthetic opioids (10.2%; CI 95%: 9.3-10.2%); and 171 synthetic 
cathinones (4.1%; CI 95% 3.5-4.7%). Conversely, the UNODC and the 
EMCDDA databases respectively included 169 and 140 cathinones. 
Overall, the three databases reported some 222 synthetic cathinones, and 
41 were uniquely identified by the NPS.Finder®.  
In terms of clinical scenarios, synthetic cathinone ingestion is initially 
associated with stimulant effects; psychopathological disturbances, 
violence, suicidal behaviour, hyperthermia, coma, and death have, 
however, been described as well. 
The proportion of cathinones commented on by psychonaut fora appeared 
to be relatively small, and similar to those reported by both the UNODC 
and EMCDDA. This may be associated with a recent significant decline in 
both cathinone-related consumption and acute medical presentation. Due 
to their complex behavioural and medical toxicity issues, healthcare 
professionals should be however be educated to recognise the signs and 




What is already known about this subject: 
 Four categories of synthetic cathinones are typically described, e.g. 
those possessing: cocaine/MDMA-related effects (e.g. 
mephedrone); MDMA-like effects (e.g. methedrone); 
methamphetamine-like effects (e.g. cathinone); and pyrovalerone-
like effects (e.g. MDPV); 
 By April 2019, the European EMCDDA database had 749 NPS 
entries, whilst the latest United Nations’ World Drug Report 
(UNODC) listed a total of 964 substances on their NPS database, 
with most molecules identified being synthetic cannabinoids and 
synthetic cathinones; 
 It could be argued that the NPS total may be higher in number than 
those described by both the UNODC and the EMCDDA, with e-





What this study adds:  
 With the help of an ad hoc crawling/navigating software 
(NPS.Finder®), designed to automatically scan the 
open/surface web, some 4204 unique NPS molecules were 
identified, with 171 (4.1%; CI 95% 3.5-4.7%) being synthetic 
cathinones;  
 NPS.Finder® has identified some 41cathinone molecules not 
known to either the UNODC or EMCDDA.   
 Clinical ill-health consequences of taking cathinones may be 
wholly consistent with their neuropsychopharmacological 
characteristics. Initial stimulant effects are associated with a 
range of acute psychiatric disturbances, including 
violence/aggression and suicidal thoughts, together with 
hyperthermia, coma, and death; 
 NPS, including synthetic cathinones, represent a challenge to 
healthcare, with complications of their use and their impact on 















Among new psychoactive substances (NPS), cathinones constitute a very 
relevant group to clinicians, policy-makers and other stake-holders 
(Guirguis et al, 2017). Mephedrone was reportedly first synthesized in 
1929 (Saem de Burnaga Sanchez, 1929). In 2007, reports of 4-
methylmethcathinone (mephedrone) use emerged, first in Israel and then 
in other countries and regions, including Australia, Scandinavia, Ireland 
and the United Kingdom (Kelly, 2011).  In 2008, it was first reported to 
the European Early Warning System by the United Kingdom and by 
Finland, after being associated with adverse health effects (EMCDDA and 
Europol, 2011). Cathinones are beta-keto derivatives of 
phenylethylamines/amphetamines which are actively being subjected to 
minor modifications at the alkyl chains or the aromatic ring to create new 
synthetic molecules with the goal of circumventing laws (Majchrzak et al, 
2018). Synthetic cathinones are usually insufflated or swallowed in their 
powder or crystal forms but can also be administered by injection, 
smoking, mucosal delivery, or injection via intramuscular or other routes 
(Schifano et al, 2015).  
 
Clinical neuropharmacological issues 
Cathinones are typically categorised based on either their pharmacological 
action or properties (Feng et al, 2017; Majchrzak et al, 2018), or in 
comparison to ‘traditional’ stimulant drugs (for a review of the issue, see 
Corkery et al, 2018). Some classifications consider their effects in relation 
to different substrates or non-substrate transporter inhibitors (Simmler et 
al, 2013). Four categories of synthetic cathinones are typically described 
in terms of their behavioural effects (for a thorough review, see Liechti, 
2015; and Guirguis et al, 2017):  
• Cocaine/3,4-Methylenedioxymethamphetamine (MDMA)-related 
effects; these are reported with a range of molecules including: 
mephedrone, 4-methylethcathinone (4-MEC), methylone, ethylone, 
butylone and naphyrone are substrates for the dopamine transporter 
(DAT), norepinephrine transporter (NET), and serotonin transporter 
(SERT) (Liechti, 2015); 
• MDMA-related effects; associated with: methedrone and 4-
trifluoromethylmethcathinone exhibit a higher inhibitory potency at SERT 
compared to their DAT activity, but at the same time promote release of 
both NE and 5-HT, like amphetamine analogues such as MDMA, 
paramethoxymethamphetamine (PMMA), paramethoxyamphetamine 
(PMA), and 4-ethylthioamphetamine (4-MTA) (Carlsson et al, 2018a; 
Simmler et al, 2014); 
• Methamphetamine-like effects; associated with: cathinone, 
methcathinone, flephedrone, ethcathinone and 3-fluoromethcathinone are 
monoamine transporter substrates with DAT selective profiles; they show 
high inhibitory potencies at DAT and exhibit lower inhibitory potencies at 
SERT (Simmler et al, 2013, 2014). They promote the release of NE and 
DA in a similar way to methylamphetamine (Liechti, 2015); 
• Pyrovalerone-like effects; associated with: pyrovalerone, MDPV and 
alpha-pyrrolidinovalerophenone (α-PVP). They are non-substrate 
transporter inhibitors, showing inhibitory potencies at NET and DAT≥ 
methylamphetamine (Aarde et al, 2013) or cocaine (Baumann et al, 
2013; Baumann et al, 2017). MDPV and α-PVP are both considered to be 
cocaine-like, whilst however being more effective reinforcers (Smith et al, 
2017). Recent research on the pyrovalerone analogue alpha-
pyrrolidinopentiothiophenone (α-PVT) suggests it has reinforcing and 
rewarding effects similar to those of both methylamphetamine and 
cocaine (Cheong et al, 2017). 
It has been suggested that the reinforcing properties of cathinone 
stimulants are positively correlated with their selectivity for the dopamine 
(DAT) relative to the serotonin transporter (SERT; Baumann et al, 2017; 
Gannon et al, 2018; Dolan et al, 2018; Glennon and Young, 2016).  
Overall, synthetic cathinone pharmacokinetics can be somewhat predicted 
considering the modifications made to the core scaffold (Calinski et al, 
2019). When ingested, the metabolic disposition of mephedrone (MEPH) 
in preclinical models is characterized by low bioavailability and an 
extensive hepatic metabolism (Martinez-Clemente et al, 2013). Its 
metabolism has been well described in rats (Meyer et al, 2010). In 
humans, Olesti et al (2019) carried out a randomized, crossover, phase I 
clinical trial. Subjects received 50 and 100 mg (n = 3) and 150 and 200 
mg (n = 6) of mephedrone. Mephedrone peak concentrations were 
reached in 1 hour, with peak plasma concentrations and the amount of 
drug recovered in urine increasing with the doses administered, 
suggesting that mephedrone presented with a linear dose-dependence. 
MEPH presented a similar elimination constant rate (K e) (at ~0.3/hour) 
and elimination half-life (t 1/2) (of ~2 hours), irrespective of the 
administered dose. Mephedrone and methylone are chemically alike; 
conversely, MDPV presents with lower Tmax and t1/2 levels and 
pentylone shows longer t1/2 (for a thorough review of the issue, see 
Calinski et al, 2019). Several phase I metabolites retain 
pharmacodynamic activity; CYP2D6 is implicated in the metabolism of all 
synthetic cathinones, and this implies that recreational users with no or 
low CYP2D6 functionality are exposed to unwanted acute toxicity episodes 
(Olesti et al, 2019). 
Up to 30% of mephedrone users may report dependence (Winstock et al, 
2011), with synthetic cathinone users possibly experiencing as well both 
tolerance and withdrawal symptoms (Zawilska et al, 2013), which include 
tiredness, insomnia, nasal congestion, and impaired concentration 
(Schifano et al, 2011). Cathinone addicts commonly report re-injecting of 
the drug with excessive binge use over long periods of time, with shorter 
half-life and duration of effects leading to more compulsive drug-taking 
behaviour to maintain euphoria (Papaseit et al, 2017).  
 
Number and types of NPS and synthetic cathinones in both real and online 
scenarios  
By April 2019, the EMCDDA European Database on New Drugs (EDND) 
database had 749 entries, whilst the latest UN World Drug Report listed a 
total of 964 substances on their NPS database (UNODC, 2018a; EMCDDA, 
2018a; EMCDDA, 2019; United Nations, 2019). Most molecules identified 
include synthetic cannabinoids and synthetic cathinones. However, it 
could be argued that the NPS scenario is much larger than that outlined 
by those molecules which have been seized and formally identified by 
both the UNODC and the EMCDDA. Since the online NPS scenario typically 
predicts the real life NPS scenario (Schifano et al, 2015; Corazza et al, 
2013), identifying what is being discussed online by web-based NPS 
enthusiasts, or ‘e-psychonauts’ (Orsolini et al, 2015; Corkery et al, 2017), 
may well be of interest.  
 
Aims 
The aim of the paper was to: (a) identify and describe the number of 
synthetic cathinones available as identified from a range of psychonaut, 
NPS-related, online sources; and (b) describe both the acute/long term 
clinical scenarios associated with synthetic cathinone intake and the 
possible treatment/management plan to best cope with the medical and 
psychopathological associated ill-health consequences.  
 
Materials and Methods  
 
a) To facilitate the process of early recognition of the increasing 
dissemination of new substances online and the variability of information 
sources, a crawling/navigating software (i.e. the ‘NPS.Finder®’) was 
designed to automatically scan the open/surface web for 
new/novel/emerging NPS (Schifano et al, 2019). This was designed to 
map on a 24/7 basis the large variety of psychoactive molecules 
mentioned/discussed within a range of major and representative online 
psychonaut websites/forums. I  
The NPS.Finder® was designed by Damicom, an IT enterprise based in 
Rome (Italy), to extract a range of information regarding NPS, including: 
chemical and street names; chemical formula; three-dimensional image; 
and anecdotally reported clinical/psychoactive effects. Resulting data 
were checked against the EMCDDA and UNODC NPS databases. The 
collection of further information was completed by consulting a range of 
open libraries and chemistry databases referring to the index item, if 
existing. These data were then automatically stored in an online, 
restricted access/password-controlled database located within firewall 
protected, highly secure, and consistently performing servers. A number 
of proper piloting searches were first carried out; with the help of most 
common search engines, including Google®, the informatics’ staff started  
navigating using a range of key words, including: NPS; novel 
psychoactive substances; new psychoactive substances; emerging 
psychoactive substances; drugs online;  buy new substances; 
psychonauts, drug forums; psychoactive products; synthetic 
cannabinoids; synthetic cathinones; psychedelic phenethylamines; novel 
stimulants; synthetic opioids; tryptamine derivatives; phencyclidine-like 
dissociatives; piperazines; GABA-A/GABA-B receptor agonists; prescribed 
medications; psychoactive plants; psychoactive herbs; and image- and 
performance-enhancing drugs. Any new website of interest was added to 
the list, whose final version is attached as Appendix 1. Although the 
language most typically used in these websites was English, further 
languages here analysed by NPS.Finder® included: Dutch, French, 
Turkish, Swedish, Spanish, German, Russian, and Italian.  
Afterwards, a range of specific web scraper/crawler activities, to extract 
all accessible posts/entries from 26th November 2017 to 31st May 2019, 
were carried out. Data were captured with the help of a range of Python 
language web crawlers, one for each font, through daily scanning 
activities. Emerging data were then imported and stored in a MYSQL 
database which presented with an SSL security protocol. All data were 
encrypted with asymmetric cryptographic procedures. Data were first 
stored in an intermediate virtual storage area. Eventually, with the help 
an ‘ad hoc’ check control panel, all data were manually and carefully 
analysed by 4 medically/psychiatrically-trained professionals (e.g. FN; 
DA; CZ; and LG). In case of data interpretation issues, these were 
resolved with the help of FS and AV. In this way, a full assessment and 
editing of each NPS.Finder® data entry was carried out and the range of 
unique synthetic cathinone molecules here commented were identified.  
When any new item was detected during the automated web scan, the 
system sent an e-mail notification/alert to the core researchers’ mailing 
list. Eventually, these data were screened for both relevance and to 
exclude possible duplications. Finally, using chemical structure 
identification and published related data, researchers assigned each 
molecule to its NPS drug class, consistent with Schifano et al (2015).  
 
b) To describe the medical and psychopathological issues most typically 
associated with the range of synthetic cathinone intake, the 
Medline/PubMed database(s) were searched for papers using the following 
keywords alone or in combination:  ‘new psychoactive substances’, ‘novel 
psychoactive substances’, ‘synthetic cathinones’, ‘medical consequences’, 
‘psychopathological consequences’, ‘psychiatric consequences’, and 
‘treatment and management of acute toxicity’, ‘clinical consequences’, 
‘mephedrone’, ‘4-methylethcathinone (4-MEC)’, ‘methylone’, ‘ethylone’, 
‘butylone’, ‘naphyrone’, ‘methedrone’, ‘4-trifluoromethylmethcathinone’, 
‘methcathinone’, ‘flephedrone’, ‘ethcathinone’, ‘3-fluoromethcathinone’, 
‘pyrovalerone’, ‘MDPV’, ‘alpha-pyrrolidinovalerophenone (α-PVP)’, and 
‘pyrrolidinopentiothiophenone (α-PVT)’.  
In assessing the abstracts that were identified by the search, the papers 
of interest were narrowed down to focus on human reports only; the 
description of both acute/chronic toxicity and dependence potential were 
included as well. 
 
Nomenclature of Targets and Ligands  
Key protein targets and ligands in this article are hyperlinked to 
corresponding entries in http://www.guidetopharmacology.org, the 




a) Data from the NPS.Finder® web crawling activities 
After about 18 months of operation, the number of substances identified 
by the web crawler activities was 5922. By the time of writing, some 4204 
unique NPS molecules were included in the database and 1718/5922 
(29.01%) remaining molecules were designated as false 
positives/duplicates. Most popular NPS mentioned in the psychonaut 
forums included: 1265 psychedelic phenethylamines (30.1%; CI 95%: 
28.7-31.5%); 1253 synthetic cannabinoids (29.8%; CI 95%: 28.4-
31.2%); 429 synthetic opioids (10.2%; CI 95%: 9.3-11.1%); and 171 
synthetic cathinones (4.1%; CI 95% 3.5-4.7%; see list in Appendix 2). 
Conversely, by the end of May 2019 the UNODC listed some 169 synthetic 
cathinones and, by 1st April 2019, the EMCDDA database included 140 
different synthetic cathinones. Overall, the three databases identified 
some 222 synthetic cathinones. More precisely, some 121 cathinones 
were common to the 3 databases; 41 were uniquely identified by the 
NPS.Finder®; 37 were identified only by the UNODC and 7 only by the 
EMCDDA (for more details, see Appendix 2). 
 ( 
b) Synthetic cathinone-related clinical issues; drafting a rational 
treatment and management plan  
The search conducted for this study identified 40 papers focussing on 
either synthetic cathinone medical/psychopathological consequences 
and/or their treatment/management approach(es).  
Clinical ill-health consequences following consumption of synthetic 
cathinones are overall consistent with their neuropsychopharmacological 
characteristics. After intake, initial stimulant effects e.g. euphoria, 
improved psychomotor speed, alertness, and talkativeness (Cheng et al, 
2012) are typically observed. Acute psychiatric effects may, however, 
include as well: low mood, loss of appetite, difficulty sleeping, a degree of 
paranoid ideation, cognitive impairment, changes in perception, agitation, 
hallucinations, delusions, amnesia, confusion, violence, suicidal thoughts 
(Homman et al 2018; Kaizer-Będkowska et al, 2018) and excited delirium 
(Penders et al, 2012). With synthetic cathinones, suicides by hanging and 
deaths from firearm injuries have frequently been reported (Schifano et 
al, 2012; Marinetti and Antonides, 2013; Barrios et al, 2016).  
Like amphetamine, synthetic cathinones result in medical side-effects 
consistent with sympathomimetic toxicity (Abbott et al, 2015; Roberts et 
al, 2017; Batisse et al, 2016). Hence, acute intoxication issues include 
hypertension, tachycardia, cardiac, kidney and liver failure, 
rhabdomyolysis, electrolyte imbalance, metabolic toxicity, paradoxical 
hypoglycaemia (Ramirez Berlioz et al, 2019), and cerebral oedema 
(Adebamiro and Perazella, 2013; Borek and Holstege, 2012; Imam et al, 
2013). Flushing, sweating, chills, restlessness, shortness of breath, dry 
mouth, abdominal pain, anorexia, vomiting, erectile dysfunction, and 
discolouration of the skin have been reported as well (Schifano et al, 
2015). Le Roux et al (2015) analyzed some105 amphetamine-like 
(including synthetic cathinones; 10% of the total) drug poisoning cases. 
The most frequently reported symptoms included anxiety and 
hallucinations (49%), mydriasis and headache (41%), tachycardia (40%) 
and hypertension (15%). Complications such as seizures (7%), cardiac 
arrest (5%), toxic myocarditis (1%) and haemorrhagic stroke (1%) were 
also observed. Cathinone-induced acute intoxication may be characterized 
as well by symptoms/signs of the serotonin syndrome, which is associated 
with hyperthermia, psychotic disorders, catatonia and hyperactive 
delirium (Weaver et al, 2015; Denysenko et al, 2015).  
Synthetic cathinone fatalities (Karila et al, 2011; Corkery et al, 2018) are 
typically attributed to hyperthermia (Kesha et al, 2013; Murray et al, 
2012), hypertension, cardiac arrest and more in general to the classic 
serotonin syndrome (Warrick et al, 2012; Zaami et al, 2018). Only rarely 
was the concentration of the parent drug causing fatality higher than 1 
mg/L in post-mortem biological fluids (Zaami et al, 2018). Ezaki et al 
(2016) compared data relating to victims from either 12 synthetic 
cathinone or cannabinoid intake and 10 methamphetamine cases. Whilst 
acute intoxication and cardiac ischaemia were the two most prominent 
causes of death in both synthetic cathinone/cannabinoid users and 
methamphetamine users, excited delirium syndrome, pulmonary 
aspiration and drowning were found only in synthetic 
cathinone/cannabinoid cases. Synthetic cathinone use alone is rare and 
the use of multiple substances may facilitate the occurrence of adverse 
effects, especially in females (for a review of the issue, see Lopez-
Rodriguez et al, 2019). Of particular concern may be the significant 
enhanced effect on central DA levels of MDPV, mephedrone, and 
methylone taken in combination (Allen et al, 2019).  
Once the initial phase of ingestion is over and the patient is medically 
stabilized, there may be a potential risk for long-term psychiatric 
problems (Salani et al, 2018; McCann et al, 1998). Furthermore, 
synthetic cathinones appear to induce neurocognitive dysfunction and 
cytotoxicity, which are dependent on drug type, dose, frequency, and 
time following exposure (Leyrer-Jackson et al, 2019). Also, orodental 
adverse effects, consistent with those observed with amphetamine, have 
been associated with a chronic exposure to synthetic cathinones (Abebe 
2018). Finally, the intravenous administration of synthetic cathinones, 
which is not limited to the context of either the ‘chemsex’ (Giorgetti et al, 
2017) or the ‘slamming’ (Batisse et al, 2016) scenarios, has been related 
to a range of behavioural problems (Schmoll et al, 2018).  
 
Cathinone categories; clinical peculiarities  
Taking into account cathinone’s pharmacological (Simmler et al, 2013) 
and behavioural effects’ classification described above (Guirguis et al, 
2017), a few differences seem to emerge between the different 
categories.  
Considering the cocaine/MDMA-mixed effects’ molecules such as 
mephedrone and related compounds, mephedrone has been the most 
investigated (De Sousa Fernandes Perna et al, 2016; Karila et al, 2016). 
Furthermore, Roberts et al (2017) found that mexedrone, a mephedrone 
derivative, was found in 11 of 305 patients who presented to an 
emergency department (ED). All of them presented with agitation and 6 
patients required sedation and/or physical restraint. Conversely, Karila et 
al (2016) emphasized that the potential chronic health effects (e.g., 
reproduction toxicity, genotoxicity and carcinogenic potential) of 
mephedrone/methylone prolonged use remain to date unknown. 
No specific clinical concerns have been described for MDMA-like effects’ 
molecules such as methedrone and 4-trifluoromethylmethcathinone. 
Conversely, in association with the misuse of methamphetamine-like 
cathinones, both Iqbal et al (2012), and Fudalej et al (2013) have 
highlighted the risk of manganese poisoning with Parkinsonism features 
reported in European clients who had injected self-prepared 
methcathinone hydrochloride (ephedrone) synthesized from 
pseudoephedrine hydrochloride using potassium permanganate as a 
potent oxidant.  
Finally, increasing levels of clinical concerns have been associated with 
the use of pyrovalerone-like molecules, including alpha-PVP and MDPV, 
whose clinical effects are individual, dose- and route of administration-
dependent (Karila et al, 2018). Palamar et al (2019) analysed data from a 
2016/2017 large scale (n = 3786) US, high school senior subjects, study. 
Overall, 0.8% (95% CI: 0.5-1.2) of seniors was estimated to have used 
alpha-PVP (‘Flakka’; ‘zombie drug’) over the previous year. Flakka users 
reported high prevalence of use of other drugs, particularly synthetic 
cannabinoids (85.6%), ketamine (72.3%), marijuana (59.1%), and GHB 
(47.5%). With alpha-PVP, a range of exaggerated symptoms, such as 
feelings of incredible strength, disorientation, aggression, and altered 
thought processes, together with high liability for abuse, tachycardia, 
agitation, hypertension, hallucinations, delirium, mydriasis, hyperthermia, 
and coma have been reported (Nóbrega and Dinis-Oliveira, 2018; Salani 
et al, 2018). Umebachi et al (2016) described a retrospective case series 
including eight subjects who had visited the local hospital ED between 
March 2012 and November 2014 and had analytically confirmed blood α-
PVP levels. Drug preparations had been administered by rectal insertion 
or inhalation; the time interval between drug intake and ED presentation 
was 8.5 (1-24) h, with blood α-PVP concentrations ranging from 1.0 to 
52.5 ng/ml. Symptoms of  high body temperature (3/8), tachycardia 
(5/8), hypertension (3/8), acid-base balance disorder (5/8), coagulopathy 
(4/6), increased blood creatinine phosphokinase (6/8), and blood lactate 
levels (5/7) were observed. Use of ‘flakka’ has been associated with at 
least 80 deaths in the US (Palamar et al, 2019). In a forensic setting, 
MDPV was detected in blood and urine samples of 50 individuals involved 
in violent crimes, including bodily harm, robberies, homicides and acts of 
resistance. In many cases, subjects showed highly aggressive and violent 
behaviour; the risk for such behaviours increased with MDPV plasma 
concentrations above 30 mg/L (Diestelman et al, 2018). According to Szili 
and Bitter (2013), in Hungary there has been an increasing number of 
hospitalized patients with acute psychosis using MDPV. Finally, 
Dzhuvalyakov et al (2017) collected post mortem samples taken from 13 
pyrrolidinovalerophenone poisoning victims from the Astrakhan region; 
they identified signs of chronic intoxication, which manifested themselves 
in the form of mixed gliosis and various lesions of brain neurons.  
 
Cathinone intake; treatment/management plan  
It is problematic to draft a universally valid treatment/management plan 
to cope with the medical, behavioural and psychopathological 
disturbances related to the intake of the virtually several hundred 
synthetic cathinones here identified, often taken in combination with the 
other traditional and new psychoactive substances (Schifano et al, 2018) 
currently available. Furthermore, it has been suggested that signs, 
symptoms, and treatment of toxicity with synthetic cathinones, synthetic 
cannabinoids, or dextromethorphan may overlap significantly (Brown et 
al, 2018; Shah and Baum, 2018). Consumers of synthetic cathinones may 
present to EDs without providing information about the substances(s) 
ingested; standard drug tests will show negative results; and 
sophisticated tests are not carried out as part of typical clinical practice 
(Schifano et al, 2016). Furthermore, neither GC-MS nor GC-FTIR alone 
can successfully differentiate between all synthetic cathinones (Carlsson 
et al, 2018b).  
Some clients may simply need reassurance, support, and medical 
monitoring. Management of cathinone, and indeed of any NPS/unknown 
psychotropics’ ingestion, is typically directed at dealing with adverse 
effects as they arise (Abdulrahim and Bowden-Jones, 2015). Due to the 
similarity of cathinones with other stimulants, management strategies 
similar to those recommended for intoxication with those drugs might be 
useful (Prosser and Nelson, 2012). For example, if a diagnosis of 
cathinone-induced delirium is suspected, treatment efforts should focus 
on controlling agitation and then treating medical complications such as 
metabolic acidosis (Abbott et al, 2015). Symptom-directed supportive 
care may also include the management of convulsions, 
hypertension/hypotension and rhabdomyolysis. Treatment of the 
cathinone-associated serotonin syndrome, which is often associated with 
agitation, may be managed using both benzodiazepines and 
cyproheptadine (Schifano et al, 2016). The observation of asymptomatic 
patients should continue for a few hours (for a review, see also 
Abdulrahim and Bowden-Jones, 2015).  
When medication is needed, given the cathinone complex/unknown 
pharmacology, benzodiazepines may be the agents of choice. Agitated 
adults be sedated with an initial dose of oral or intravenous diazepam 
(0.1–0.3 mg/kg body weight). At times, larger doses/frequent re-dosing 
to achieve adequate sedative effect may be required (Abdulrahim and 
Bowden-Jones, 2015; TOXBASE, 2019).  Further targeted treatment to 
control aggression and agitation may include intramuscular or intranasal 
midazolam, or intramuscular lorazepam. This approach may be useful as 
well to stop seizures (Guirguis et al, 2017). Benzodiazepines, however, 
may be a problem whilst in presence of alcohol and, where patients 
cannot be controlled with benzodiazepines alone, propofol and/or 
antipsychotics may be considered. However, drugs such as haloperidol, 
olanzapine, or ziprasidone can lower seizure thresholds, and contribute to 
dysrhythmias (Schifano et al, 2016). In general, the use of atypical 
antipsychotics including the psychonauts’ ‘ideal trip terminator’ (Valeriani 
et al, 2015) olanzapine, has shown good efficacy in containing episodes of 
aggression in different cohort and different phases of illness (Mauri et al, 
2011). Finally, treatment for patients with prolonged exposure to 
synthetic cathinones should ideally include a drug management plan 




The present paper provides unique, unprecedented, figures in terms of 
overall numbers of synthetic cathinones; it presents as well with an 
overview of the ill-health effects associated with the ingestion of these 
compounds, which are intended to mimic the effects of traditional 
stimulants.  
The number of synthetic cathinones here identified with NPS.Finder® was 
comparable with that identified by the UNODC, and higher than that listed 
in the EMCDDA database. Out of the 222 synthetic cathinones overall 
identified by the 3 databases, NPS.Finder® captured 171/222 (77%) of 
them, a performance figure very similar to the UNODC one (169/222; 
76%), but better than the EMCDDA one (140/222; 63%). One could 
argue that these differences may be due to the EMCDDA focusing on 28 
EU countries only, whilst both the UNODC database and the psychonaut 
entries may better reflect the global situation.  
Conversely, in comparison with remaining approaches, one would have 
hypothesized with the NPS.Finder® approach the mention by psychonauts 
of a much larger number of synthetic cathinones. In fact, if one considers 
the whole number of molecules identified through analysis of data based 
on psychonauts’ discussions, the NPS.Finder® database has identified a 
quantitative level of NPS which is about 5-fold higher than those 
mentioned by both the UNODC and the EMCDDA (Schifano et al, 2019). It 
is of interest to note, however, that synthetic cathinones accounted here 
for only 4.1% of the whole number of web crawler database molecules. 
This is in sharp contrast with UNODC data, where synthetic cathinones 
are second only to synthetic cannabinoids/’spice’ in terms of number of 
NPS seized over the years (UNODC, 2018b). Similarly, synthetic 
cathinones were the NPS most seized in 2016 in the EU (EMCDDA 2018b).  
On the other hand, psychonauts may well focus their discussions, more 
than anything else, on those issues which are topical (Orsolini et al, 
2015). Consistent with this, it is of interest to note that Webb et al (2019) 
found that cathinone-related presentations to UK EDs, over the last 
couple of years, significantly declined in number. Furthermore, the 
England and Wales 2017 survey data showed that last year mephedrone 
use among 16- to 34-year-olds was estimated at 0.2%, down from 1.1% 
in 2014/15 (EMCDDA, 2019). This is echoed by a fall in the number and 
quantity of mephedrone seized by UK law enforcement agencies (Home 
Office, 2018a; 2018b; Scottish Government, 2019; PSNI, 2019), as well 
as those presenting for treatment for mephedrone in England (PHE 
2018a; 2018b), and those whose deaths involved mephedrone (Corkery 
et al, 2018). In other words, there might have been a recent decline in 
interest towards synthetic cathinones, and one could wonder if this is 
linked to increased availability of higher purity/high dose 
MDMA/psychedelic phenethylamine products (EMCDDA, 2019). One could 
also argue that the market has reached a point of saturation for 
molecules being offered to synthetic cathinone enthusiasts.  
From the present overview, it seems that together with the vast range of 
NPS, synthetic cathinones represent a clinical challenge, with 
complications of their use and their impact on services still being 
relatively unknown (Henshall et al, 2018). Indeed, synthetic cathinone 
intake is typically associated with an imbalance of a range of 
neurotransmitter pathways/receptors, and consequently with a significant 
risk of both medical and psychopathological disturbances, at times 
accompanied by bizarre behaviour and significant violence/aggression 
levels (Schifano et al, 2015). Only a paucity of information exists on the 
biological, physiological, and toxicological effects of synthetic cathinones, 
especially regarding their long-term effects after heavy and prolonged 
use. It is paramount that healthcare professionals are able to recognize 
the signs and symptoms of synthetic cathinone ingestion, know the steps 
to take to ensure safety of the patient and those around him or her 
(Salani et al, 2018).  
Vulnerable subjects, including both children/adolescents and psychiatric 
patients, may be exposed to large number of pro drug web pages, from 
which anecdotal levels of knowledge related to both well-known and novel 
psychotropics are typically provided by ‘e-psychonauts’ (e.g. drug 
forums/blog communities’ members). Hence, future approaches should 
consider the role of web-based preventative strategies in targeting 
youngsters/vulnerable individuals at risk of approaching the drug market.  
 
Limitations 
It has to be emphasized here that the NPS.Finder® crawled so far on the 
open web only. Since there may well be further information available on 
both the deep web and the dark net, future studies of our group will be 
focussing on expanding drug searches on these less accessible areas of 
the web. NPS.Finder®-based studies will need to focus as well on further 
languages, which should include as well: Chinese; Japanese; and Arabic, 
since previous studies have highlighted their importance in NPS-based 
studies (Deluca et al, 2012). Furthermore, from a formal point of view the 
current literature review would not be considered as ‘systematic’. Instead, 
it was conceived as a literature overview, focussing on the cathinone 
clinical issues of interest.  
 
Conclusions 
More studies should aim at providing better levels of misusing drugs’ 
clinical pharmacological-related knowledge, so that properly tailored 
management/treatment strategies and guidelines can be drawn up and 
made available.  
Because of the complex behavioural and medical toxicity issues, raising 
awareness of and education on drugs’ health harms, interventions, harm 
reduction techniques, and referral pathways are here considered to be of 
relevance for health care professionals (Guirguis et al, 2017; Pourmand et 
al, 2018). 
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Appendix 1: List of websites monitored by the NPS.Finder® web crawler 
during the time frame November 2017-May 2019; surface web only 
  








































Y Y Y 
4 1-(1,3-benzodioxol-5-yl)-2-
(propylamino)butan-1-one 




Y Y Y 
5 1-(2,3-dihydro-1H-inden-5-yl)-2-
(ethylamino)pentan-1-one 




Y Y Y 
6 1-(2,3-dihydro-1H-inden-5-yl)-2-
(methylamino)propan-1-one 
































































Y N Y 
13 1-(3-fluorophenyl)-2-(pyrrolidin-1-
yl)pentan-1-one   
3F-α-PVP, 3F-alpha-PVP  1-(3-fluorophenyl)-2-
(pyrrolidin-1-
yl)pentan-1-one  







































Y Y Y 
19 1-(4-chlorophenyl)-2-(pyrrolidin-1-
yl)propan-1-one 
 4’-chloro-α-PPP  1-(4-chlorophenyl)-2-
(pyrrolidin-1-
yl)propan-1-one 




















Y Y Y 
22 1-(4-fluorophenyl)-2-(piperidin-1-
yl)pentan-1-one  





















































Y N N 
28 1-(4-Methylphenyl)-2-ethylaminobutan-
1-one  
18268-19-4; 4-Me-NEB  2-(ethylamino)-1-(p-
tolyl)butan-1-one 

















Y Y Y 














Y N N 




Y Y Y 





























































Y Y Y 
41 2-aminopropan-1-one  2-Aminopropanone 2-Aminopropan-1-one N N Y 
42 2-aminopropiophenone 1-aminoethyl, phenyl ketone  2-amino-1-
phenylpropan-1-one; 
N N Y 
43 2-chloroethcathinone  2-CEC  1-(2-chlorophenyl)-2-
(ethylamino)propan-1-
one 
Y N N 
44 2-Ethyl-N-ethylcathinone  2-EEC  2-(ethylamino)-1-(2-
ethylphenyl)propan-1-
one 
Y N N 
45 2-Ethyl-N-methylcathinone  2-EMC  2-
[ethyl(methyl)amino]-
1-phenylpropan-1-one 
Y N N 



































Y N N 
51 2-Methyl-1-phenyl-2-(3-pyridinyl)-1-
propanone 
2-MPPP n-piperidinecathinone N N Y 
52 2-Methyl-N-methylcathinone 2-methylethylcathinone; 2-
methylethcathinone; 2-MEC  
2-(ethylamino)-1-(o-
tolyl)propan-1-one 
Y Y Y 
53 2-Methylethcathinone  2-MEC; 2-methylethylcathinone; 2-(ethylamino)-1-(o-
tolyl)propan-1-one 














Y Y Y 




Y N N 






Y N N 




Y Y Y 
59 2,5-dimethoxycathinone 2,5-DMA-bk; 2,5-DMA-βk 2-Amino-1-(2,5-
dimethoxyphenyl)prop
an-1-one 
N N Y 








Y Y Y 
61 3-chloroethcathinone  3-CEC  1-(3-chlorophenyl)-2-
(ethylamino)propan-1-
one 
Y Y N 





Y Y Y 
63 3-Ethyl-N-ethylcathinone 3-EEC  2-(ethylamino)-1-(2-
ethylphenyl)propan-1-
one 
Y N N 
64 3-ethylmethcathinone  3-EMC  1-(3-ethylphenyl)-2-
(methylamino)propan-
1-one 
Y N N 




Y N N 















Y Y Y 






Y Y Y 
69 3-Methylethcathinone  3-MEC; 3-Methylethylcathinone 2-(ethylamino)-1-(m-
tolyl)propan-1-one 
Y Y Y 




Y Y Y 
71 3-methylmethcathinone  3-MMC; metaphedrone (RS)-2- 
(methylamino)- 1- (3- 
methylphenyl)- 1- 
propanone 








Y Y Y 




















Y Y Y 





Y N N 





Y N N 




Y N N 
78 3,4-Dimethylethcathinone  3,4-DMEC  1-(3,4-
dimethylphenyl)-2-
Y Y Y 
(ethylamino)propan-1-
one 




Y Y Y 




Y Y Y 
















Y Y Y 








Y Y Y 
84 3,4-methylenedioxy-N-tert-
butylcathinone  
tBuONE; MDPT; D-Tertylone 3,4-Methylenedioxy-N-
tert-butylcathinone 














































Y Y Y 
88 3,4-Methylenedioxycathinone  BK-MDA  2-amino-1-(1,3-
benzodioxol-5-
yl)propan-1-one 
Y N N 
89 3,4-Methylenedioxypyrovalerone  687603-66-3; MDPV; 
Methylendioxypyrovalerone; 






Y Y Y 








N Y Y 
91 4-Bromo-alpha-pyrolidinovalerophenone  4Br-alpha-PVP  1-(4-Bromophenyl)-2-
(1-pyrrolidinyl)-1-
pentanone 
Y Y Y 
92 4-Bromoethcathinone  4-BEC  1-(4-bromophenyl)-2-
(ethylamino)-1-
propanone 
Y Y Y 





















95 4-chloro-N,N-dimethylcathinone  4-CDMC, 4-CDC  4-chloro-N,N-
dimethylcathinone 
Y Y Y 






Y Y Y 
97 4-chloroethcathinone  4-CEC  1-(4-chlorophenyl)-2-
(ethylamino)-1-
propanone 
Y Y Y 
98 4-chloromethcathinone  4-CMC, CLEPHEDRONE 1-(4-chlorophenyl)-2-
(methylamino)-1-
propanone 
Y Y Y 







Y Y Y 
100 4-Cl-EAPP  4-Cl-alpha-EAPP  1-(4-chlorophenyl)-2-
(ethylamino)pentan-1-
one 
Y N N 








Y Y Y 
102 4-Ethylmethcathinone  1225622-14-9, 4-EMC  1-(4-ethylphenyl)-2-
(methylamino)propan-
1-one 
Y Y Y 
103 4-ethylpentedrone 4-EPD 1-(4-ethylphenyl)-2-
(methylamino)pentan-
1-one 
N N Y 















Y Y Y 
106 4-fluoro-alpha-pyrrolidinovalerophenone  4-F-PVP; 850352-31-7 4F-alpha-
PVP; 4f-a-pvp; pfpvp; 4′-Fluoro-
α-pyrrolidinopentiophenone; 4F-




Y Y Y 





Y Y Y 





Y Y Y 







Y Y N 
110 4-Fluorocathinone  4-FC 2-amino-1-(4-
fluorophenyl)propan-1-
one 
Y Y Y 
111 4-fluoroethcathinone  4-FEC  2-(Ethylamino)-1-(4-
fluorophenyl)propan-1-
one 
Y Y N 
112 4-Fluoroisocathinone  4-FIC  1-amino-1-(4-
fluorophenyl)propan-2-
one 
Y N N 







Y Y Y 





Y N N 



































Y Y Y 
119 4-methoxy-N-ethylcathinone   bk-PMEA 2-(ethylamino)-1-(4-
methoxyphenyl)propan
-1-one 
Y N N 










Y Y Y 




Y N N 












Y N N 














N Y Y 
126 4-methyl-N,N-dimethylcathinone 4-MDMC  4-Methyl-N,N-
dimethylcathinone 
Y Y Y 




















Y Y Y 
129 4-Methyl-α-pyrrolidinopropiophenone  1313393-58-6; MPPP; 4'-methyl-





Y Y Y 











Y Y Y 




Y N N 






Y Y Y 






Y Y Y 
4-methyl ephedrone; Meow 







N Y N 













N Y N 






Y Y Y 
138 5-dihydrobenzofuranpyrovalerone  5-DBFPV  5-
dihydrobenzofuranpyro
valerone 
Y Y Y 




N N Y 





N N Y 
141 alpha-Aminobutyrophenone  67323-52-8  2-amino-1-
phenylbutan-1-one 
Y N N 







Y Y Y 








Y Y Y 





N Y Y 





Y N N 
146 alpha-PVT α-Pyrrolidinopentiothiophenone 2-(Pyrrolidin-1-yl)-1-
(thiophen-2-yl)pentan-
1-one 
N Y Y 






Y Y Y 




Y Y Y 
149 alpha-pyrrolidinoheptiophenone  alpha-PEP, alpha-PHPP, PV8  1-phenyl-2-(pyrrolidin-
1-yl)heptan-1-one 
Y Y Y 






Y Y Y 






Y Y Y 






































 bk-DMBDB; bk-MMBDB; 
Dibutylone; Methylbutylone; m-
butylone; N-methylbutylone; 










Y Y Y 
156 BK-MPA MTP, THIOTHINONE 2-(methylamino)-1-
(thiophen-2-yl)propan-
1-one 







N N Y 




N Y N 







N N Y 
160 Cyclohexane analogue of mephedrone   2-(methylamino)-1-(4-
methylcyclohexyl)prop
an-1-one 
N N Y 









N N Y 




Y N N 






Y Y Y 






N N Y 









Y Y Y 
166 Ethcathinone  51553-17-4; Ethylpropion; EC, 
Ethyl cathinone; Ethcathinone; 










Y Y Y 
167 Ethylnaphthidate  HDEP-28  Ethyl 2-naphthyl(2-
piperidinyl)acetate 
Y N N 









Y Y Y 
methylenedioxyphenyl)propan-
1-one 






Y Y Y 































Y Y Y 




Y N Y 




Y N Y 






Y N N 







N N Y 






N N Y 






N N Y 








N N Y 






N N Y 






N N Y 






N N Y 






N N Y 






N N Y 
186 Methcathinone Methcath; Ephedrone; Jee 
Cocktail; monomethylpropion; 








N N Y 
(METHYLAMINO)-1-PHENYL-; 
LPLLVINFLBSFRP-UHFFFAOYSA-






No. 1237; BDBM86285; 
KBio1_000966; NINDS_000966; 
CAS_1576; NSC_1576; AL-422; 












187 Methylone  196028-79-5 bk-MDMA; βk-
MDMA; M1; MDMC; 3,4-
methylenedioxy-N-
methylcathinone; MDMCAT; 
MDMC ; Explosion; Room 





Y Y Y 











N N Y 




N N Y 
190 Mexedrone  4-MMC-oMe; MEX 3-methoxy-2-
(methylamino)-1-(p-
tolyl)propan-1-one 
Y Y Y 






Y N N 
192 N-acetyl-3-methylmethcathinone  N-Ac-3-MMC  N-methyl-N-(1-oxo-1-
(m-tolyl)propan-2-
yl)acetamide 








Y N N 


















N Y N 
197 N-Ethyl hexylone 2-ETHYL-1,3-HEXANEDIOL; 94-
96-2; Ethohexadiol; 2-
Ethylhexane-1,3-diol; 1,3-
Hexanediol, 2-ethyl-; Octylene 
glycol; Ethyl hexanediol; Carbide 
6-12; Repellent 612; Rutgers 








N N Y 
2-Ethyl-1,3-hexandiol; 
Ethylhexylene glycol; ENT 375; 
Ethohexadiol [USP]; Caswell No. 
445; 6-12 insect repellent; Latka 
612 [Czech]; NSC 3881; CCRIS 
4034; Ethyl hexylene glycol; 
Compound 6-12 insect repellent; 
HSDB 1716; 2-Ethylhexanediol-
1,3; EINECS 202-377-9; EPA 
Pesticide Chemical Code 041001; 
BRN 1735324; AI3-00375; 









etohexadiol; CAS-94-96-2; Latka 
612; 2-Ethyl-1,3-hexanediol, 
99%, mixture of isomers; 
ethohexadiol(r); EH diol; 
AC1Q2UNQ; EC 202-377-9; 2-
ethyl-1,3-hexane diol; 2-ethyl-
hexane-1,3-diol; Ethyl-1,3-




















23711; S173; TR-033135; 2-
Ethyl-1,3-hexanediol, analytical 















Y Y Y 














N Y N 
201 N-ethylhexedrone NEH, HEXEN; Ethyl-Hexedrone 
Powder; α-
ethylaminocaprophenone; N-





Y Y Y 










N Y Y 







Y Y Y 










Y Y Y 
205 Naphthylpyrovalerone  850352-53-3 O-2482; 





Y Y Y 






Y Y Y 










Y Y Y 












N N Y 












N N Y 
212 Propylcathinone  Propylcathinone; N-
propylcathinone; N-mono-n-




Y Y Y 




Y Y Y 
214 Pyrophenidone α-Phenyl-Pyrovalerone 2-phenyl-2-(pyrrolidin-
1-yl)-1-(p-
tolyl)ethanone 
N N Y 
215 Pyrovalerone Centroton, 4-Methyl-β-keto-
prolintane, Thymergix, O-2371; 
Centroton; 4-Methyl-β-keto-





N N Y 
216 PZAP   2-(4-Methylpiperazin-
1-yl)-1-phenylpropan-
1-one 
N N Y 






N N Y 





N N Y 






Y Y N 










Y Y Y 






Y Y Y 
222 α-pyrrolidinovalerophenone or alpha-
Pyrrolidinovalerophenone  
14530-33-7 α-PVP, O-2387, 












Y Y Y 
 
Appendix 2: Synthetic cathinones listed in the NPSfinder®; UNODC; and 
EMCDDA databases.  
  
 
List of Hyperlinks for Crosschecking 
amphetamines 
Cocaine 
MDMA 
DAT 
NET 
SERT 
Methamphetamine 
NE 
5-HT 
Methamphetamine 
DA 
GABA-A 
GABA-B 
diazepam 
midazolam 
lorazepam 
haloperidol 
olanzapine 
ziprasidone 
 
 
 
 
